IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0665810
(2000-09-20)
|
발명자
/ 주소 |
- Rouillard, Jean
- Comte, Christophe
- Daigle, Dominik
- Hagen, Ronald A.
- Knudson, Orlin B.
- Morin, Andre
- Ranger, Michel
- Ross, Guy
- Rouillard, Roger
- St-Germain, Philippe
- Sudano, Anthony
- Turgeon, Th
|
출원인 / 주소 |
- 3M Innovative Properties Company, Hydro-Quebec Corporation
|
인용정보 |
피인용 횟수 :
13 인용 특허 :
149 |
초록
▼
The present invention is directed to an improved electrochemical energy storage device. The electrochemical energy storage device includes a number of solid-state, thin-film electrochemical cells which are selectively interconnected in series or parallel through use of an integrated interconnect boa
The present invention is directed to an improved electrochemical energy storage device. The electrochemical energy storage device includes a number of solid-state, thin-film electrochemical cells which are selectively interconnected in series or parallel through use of an integrated interconnect board. The interconnect board is typically disposed within a sealed housing which also houses the electrochemical cells, and includes a first contact and a second contact respectively coupled to first and second power terminals of the energy storage device. The interconnect board advantageously provides for selective series or parallel connectivity with the electrochemical cells, irrespective of electrochemical cell position within the housing. Fuses and various electrical and electromechanical devices, such as bypass, equalization, and communication devices for example, may also be mounted to the interconnect board and selectively connected to the electrochemical cells.
대표청구항
▼
The present invention is directed to an improved electrochemical energy storage device. The electrochemical energy storage device includes a number of solid-state, thin-film electrochemical cells which are selectively interconnected in series or parallel through use of an integrated interconnect boa
The present invention is directed to an improved electrochemical energy storage device. The electrochemical energy storage device includes a number of solid-state, thin-film electrochemical cells which are selectively interconnected in series or parallel through use of an integrated interconnect board. The interconnect board is typically disposed within a sealed housing which also houses the electrochemical cells, and includes a first contact and a second contact respectively coupled to first and second power terminals of the energy storage device. The interconnect board advantageously provides for selective series or parallel connectivity with the electrochemical cells, irrespective of electrochemical cell position within the housing. Fuses and various electrical and electromechanical devices, such as bypass, equalization, and communication devices for example, may also be mounted to the interconnect board and selectively connected to the electrochemical cells. , wherein said amount of said at least one effervescent penetration enhancer is at least about two times the amount of said drug; and (c) an enteric coating maintained over said drug and said at least one effervescent penetration enhancer; wherein said enteric coating prevents the release of said drug and said at least one effervescent penetration enhancer until a time at which said dosage form reaches said target area in said gastrointestinal tract. 2. The dosage form of claim 1, wherein said amount of said at least one effervescent penetration enhancer is equal to about two times the amount of said drug. 3. The dosage form of claim 1, wherein said amount of said at least one effervescent penetration enhancer is at least about three times the amount of said drug. 4. The dosage form of claim 3, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of said drug. 5. The dosage form of claim 3, wherein said at least one effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said effervescent couple comprising an acid or equivalent thereof and a base or equivalent thereof. 6. The dosage form of claim 5, wherein said base or equivalent thereof is present in an amount equal to or greater than about two times the amount of said drug; and said acid is present in an amount approximately equimolar to said base. 7. The dosage form of claim 6, wherein said base or equivalent thereof is present in an amount equal to or greater than about three times the amount of said drug. 8. The dosage form of claims 1 or 3, further comprising a pH adjusting substance. 9. The dosage form of claims 1 or 3, further comprising a bioadhesive, wherein said bioadhesive increases contact time between said drug and a mucosal layer of said target area. 10. The dosage form of claim 9, wherein said bioadhesive is contained in a portion of said dosage form external to said drug. 11. The dosage form of claims 1 or 3, further comprising at least one noneffervescent penetration enhancer. 12. The dosage form of claims 1 or 3, further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid dispersion of said drug to said target area of said gastrointestinal tract. 13. The dosage form of any one of claims 1 or 3, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area of the gastrointestinal tract to release said drug and said effervescent penetration enhancer. 14. The dosage form of claims 1 or 3, wherein said dosage form is a tablet. 15. The dosage form of claims 1 or 3, wherein said dosage form is a capsule. 16. The dosage form of claims 1 or 3, wherein said dosage form is in the form of granules. 17. The dosage form of any one of claims 1 or 3, wherein said dosage from is in the form of pellets. 18. The dosage form of claim 14, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug and said effervescent penetration enhancer are located in said biconcave zone. 19. The dosage form of claim 18, wherein said two outer zones contain a bioadhesive. 20. The dosage form of claim 5, wherein said base is sodium bicarbonate. 21. The dosage form of claim 1, wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract. 22. The dosage form of claim 21, wherein said target area is selected from the group consisting of stomach, duodenum, intestines, and colon. 23. The dosage form of claims 1 or 3, wherein said dosage form is a tablet, and said effervescent penetration enhancer is present in the amount of between about 5% and about 95% based on the weight of said tablet. 24. The dosage form of claim 23, wherein said effervescent penetration enhancer is present in the amount of between about 30% to about 60% based on the weight of said tablet.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.